J Burgos1, A Curran1, S Landolfi2, J Navarro1, N Tallada2, A Guelar3, M Crespo1, I Ocaña1, E Ribera1, V Falcó1. 1. Infectious Diseases Department, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute (VHIR), Autonomous University of Barcelona, Barcelona, Spain. 2. Anatomical Pathology Department, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain. 3. Internal Medicine Department, Mar University Hospital, Autonomous University of Barcelona, Barcelona, Spain.
Abstract
OBJECTIVES: Electrocautery is one of the main treatment options for high-grade anal intraepithelial neoplasia (HGAIN). However, data regarding its efficacy are scarce. The aim of the study was to evaluate the effectiveness of electrocautery for the treatment of HGAIN. METHODS: An observational study of HIV-infected men who have sex with men (MSM) who underwent screening for anal dysplasia was carried out. The on-treatment effectiveness of electrocautery was evaluated (according to biopsy findings measured 6-8 weeks after treatment) in patients with HGAIN. A complete response was defined as resolution of anal intraepithelial neoplasia (AIN), a partial response as regression to low-grade AIN and recurrence as biopsy-proven HGAIN during follow-up. RESULTS: From May 2009 to November 2014, 21.9% (126 of 576) of patients screened were found to have HGAIN. Electrocautery effectiveness was evaluated in 83 patients. A complete response was observed in 27 patients [32.5%; 95% confidence interval (CI) 23.4-53.2%], a partial response in 28 patients (33.7%; 95% CI 24.5-44.4%) and persistence in 28 patients (33.7%; 95% CI 24.5-44.4%). The patients with the most successful results (81.8%) required two to four sessions of electrocautery. After a mean follow-up of 12.1 months, 14 of 55 patients with a response (25.4%; 95% CI 15.8-38.3%) developed recurrent HGAIN within a mean time of 29.9 months (95% CI 22-37.7 months). No patient progressed to invasive cancer during the study or developed serious adverse events after treatment. No factors associated with poor response or recurrences were observed. CONCLUSIONS: Although electrocautery is the standard treatment for anal dysplasia, almost 50% of patients with HGAIN in our study did not respond or relapsed. New treatment strategies are necessary to optimize the management of anal dysplasia.
OBJECTIVES: Electrocautery is one of the main treatment options for high-grade anal intraepithelial neoplasia (HGAIN). However, data regarding its efficacy are scarce. The aim of the study was to evaluate the effectiveness of electrocautery for the treatment of HGAIN. METHODS: An observational study of HIV-infectedmen who have sex with men (MSM) who underwent screening for anal dysplasia was carried out. The on-treatment effectiveness of electrocautery was evaluated (according to biopsy findings measured 6-8 weeks after treatment) in patients with HGAIN. A complete response was defined as resolution of anal intraepithelial neoplasia (AIN), a partial response as regression to low-grade AIN and recurrence as biopsy-proven HGAIN during follow-up. RESULTS: From May 2009 to November 2014, 21.9% (126 of 576) of patients screened were found to have HGAIN. Electrocautery effectiveness was evaluated in 83 patients. A complete response was observed in 27 patients [32.5%; 95% confidence interval (CI) 23.4-53.2%], a partial response in 28 patients (33.7%; 95% CI 24.5-44.4%) and persistence in 28 patients (33.7%; 95% CI 24.5-44.4%). The patients with the most successful results (81.8%) required two to four sessions of electrocautery. After a mean follow-up of 12.1 months, 14 of 55 patients with a response (25.4%; 95% CI 15.8-38.3%) developed recurrent HGAIN within a mean time of 29.9 months (95% CI 22-37.7 months). No patient progressed to invasive cancer during the study or developed serious adverse events after treatment. No factors associated with poor response or recurrences were observed. CONCLUSIONS: Although electrocautery is the standard treatment for anal dysplasia, almost 50% of patients with HGAIN in our study did not respond or relapsed. New treatment strategies are necessary to optimize the management of anal dysplasia.
Authors: G A Binda; G Gagliardi; I Dal Conte; M Verra; P Cassoni; E Cavazzoni; E Stocco; S Delmonte; P De Nardi; L Sticchi; M Mistrangelo Journal: Tech Coloproctol Date: 2019-06-26 Impact factor: 3.781
Authors: Matthijs L Siegenbeek van Heukelom; Karien C M Gosens; Jan M Prins; Henry J C de Vries Journal: Am J Clin Dermatol Date: 2018-02 Impact factor: 7.403
Authors: A Leeman; D Jenkins; E Marra; M van Zummeren; E C Pirog; M M van de Sandt; A van Eeden; M F Schim van der Loeff; J Doorbar; H J C de Vries; F J van Kemenade; C J L M Meijer; W G V Quint Journal: Br J Dermatol Date: 2019-10-02 Impact factor: 9.302
Authors: Carmen Hidalgo-Tenorio; Carmen Maria García-Martínez; Juan Pasquau; Mohamed Omar-Mohamed-Balgahata; Miguel López-Ruz; Javier López-Hidalgo; Concepción Gil-Anguita Journal: PLoS One Date: 2021-02-03 Impact factor: 3.240
Authors: Danielle R L Brogden; Una Walsh; Gianluca Pellino; Christos Kontovounisios; Paris Tekkis; Sarah C Mills Journal: Int J Colorectal Dis Date: 2020-09-26 Impact factor: 2.796